Effects of glucagon‐like peptide‐1 analogs on prolactin levels: A secondary analysis of a randomized, double‐blind, placebo‐controlled crossover trial
- 1Department of Endocrinology, Diabetology and Metabolism University Hospital Basel Basel Switzerland
- 2Department of Clinical Research University of Basel Basel Switzerland
- 3Department of Endocrinology, Diabetology and Clinical Nutrition University Hospital Zurich Zurich Switzerland
Abstract
Prolactin (PRL) is involved in the modulation of sexual function. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been proposed to modulate reward‐related processes beyond their effects on appetite, including sexual desire. In our previously published randomized parent trial of dulaglutide and sexual desire, we hypothesized that any potential effect on sexual desire could involve changes in PRL concentrations. Predefined secondary analysis of a single‐center randomized, double blind, placebo‐controlled, crossover trial involving 24 healthy eugonad men of normal weight (BMI 18.5–25 kg/m2 or BMI 25.1–30 kg/m2 and waist circumference <102 cm). PRL concentrations were the primary outcome of the present analysis and were measured at baseline and after 4 weeks of dulaglutide (1.5 mg s.c. weekly) and placebo treatment, alongside weight, appetite, and sexual desire. Median age of participants was 24.5 years (IQR [21.0, 29.0]), median BMI was 23.9 kg/m2 (IQR [22.2, 25.0]). PRL levels changed by −31.1 mU/L (SD 87.0 mU/L) on dulaglutide and +44.6 mU/L (SD 113.1 mU/L) on placebo over 4 weeks (estimated difference: −149.3 mU/L; 95% CI: [−298.5, −0.1]). On dulaglutide treatment, reductions in PRL correlated weakly with weight loss (r = 0.25), and more than half of participants (13/24) showed parallel decreases in PRL and appetite scores. Regarding sexuality, we found no association of PRL levels and sexual desire. Four weeks of dulaglutide treatment reduced PRL concentrations compared with placebo in healthy men. These findings may point to broader neuroendocrine effects of GLP‐1 receptor activation and warrant further investigation.
Trial registration: ClinicalTrials.gov NCT04687514.
Related
- Effects of Breakfasts with Different Carbohydrate Contents and Glycemic Index Values on Postprandial Subjective Satiety and Plasma Gut Hormone Concentrations in Healthy Adults: An Exploratory Secondary Analysis of an Acute Randomized Crossover Controlled-Feeding Study
- Loop Taping for Heel Fat Pad Syndrome: A Crossover Pilot Randomized Controlled Trial
- DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo Controlled Crossover Trial
- Glabridin content and metabolic effects of liquorice confectionaries: A secondary analysis of a randomized crossover trial in young adults
- Metabolic and neural responses to ultraprocessed foods: a randomized, controlled, crossover study.
BibTeX
@article{reber2026effects,
title = {{Effects of glucagon‐like peptide‐1 analogs on prolactin levels: A secondary analysis of a randomized, double‐blind, placebo‐controlled crossover trial}},
author = {Vera Reber and Cyrill Denis Mueller and Sophia Lengsfeld and Leila Probst and Laura Werlen and Richard Allen and Yara Emara and Cemile Bathelt and Bettina Winzeler},
journal = {Journal of Neuroendocrinology},
year = {2026},
month = nov,
doi = {10.1111/jne.70308},
url = {https://doi.org/10.1111/jne.70308},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effects of glucagon‐like peptide‐1 analogs on prolactin levels: A secondary analysis of a randomized, double‐blind, placebo‐controlled crossover trial
AU - Vera Reber
AU - Cyrill Denis Mueller
AU - Sophia Lengsfeld
AU - Leila Probst
AU - Laura Werlen
AU - Richard Allen
AU - Yara Emara
AU - Cemile Bathelt
AU - Bettina Winzeler
PY - 2026
DA - 2026/11/05
JO - Journal of Neuroendocrinology
DO - 10.1111/jne.70308
UR - https://doi.org/10.1111/jne.70308
AB - Prolactin (PRL) is involved in the modulation of sexual function. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been proposed to modulate reward‐related processes beyond their effects on appetite, including sexual desire. In our previously published randomized parent trial of dulaglutide and sexual desire, we hypothesized that any potential effect on sexual desire could involve changes in PRL concentrations. Predefined secondary analysis of a single‐center randomized, double blind, placebo‐controlled, crossover trial involving 24 healthy eugonad men of normal weight (BMI 18.5–25 kg/m2 or BMI 25.1–30 kg/m2 and waist circumference <102 cm). PRL concentrations were the primary outcome of the present analysis and were measured at baseline and after 4 weeks of dulaglutide (1.5 mg s.c. weekly) and placebo treatment, alongside weight, appetite, and sexual desire. Median age of participants was 24.5 years (IQR [21.0, 29.0]), median BMI was 23.9 kg/m2 (IQR [22.2, 25.0]). PRL levels changed by −31.1 mU/L (SD 87.0 mU/L) on dulaglutide and +44.6 mU/L (SD 113.1 mU/L) on placebo over 4 weeks (estimated difference: −149.3 mU/L; 95% CI: [−298.5, −0.1]). On dulaglutide treatment, reductions in PRL correlated weakly with weight loss (r = 0.25), and more than half of participants (13/24) showed parallel decreases in PRL and appetite scores. Regarding sexuality, we found no association of PRL levels and sexual desire. Four weeks of dulaglutide treatment reduced PRL concentrations compared with placebo in healthy men. These findings may point to broader neuroendocrine effects of GLP‐1 receptor activation and warrant further investigation. Trial registration: ClinicalTrials.gov NCT04687514.
SN - 0953-8194
SN - 1365-2826
ER -